Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Xiamen, Fujian

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

  • Sample Provided: yes

    Payment Terms: L/L

    Product Information

     

    Product name

    Vonoprazan Fumarate

    Molecular Formula

    C21H20FN3O6S

    Molecular Weight

    461.46

    CAS No.

    1260141-27-2

    Quality Standard

    99% up

    Appearance

    White crystalline powder

     

    COA of Vonoprazan Fumarate

     

    Test items

    Specifications

    Result

    Appearance

    White or almost white crystalline powder

    White crystalline powder

    Solubility

    Soluble in DMSO, slightly soluble in methanol and water, very slightly soluble in ethanol

    Complied

    Identification (HPLC)

    Must comply with enterprise standard

    Complied

    Test:

     

     

    Loss on drying

    ≤0.5%

    0.02%

    Residue on ignition

    ≤0.1%

    0.08%

    Heavy metals

    ≤20ppm

    Complied

    Related Substances:

     

     

    Individual impurity

    ≤0.5%

    0.10%

    Total impurities

    ≤1.0%

    0.15%

    Conclusion

    The product complies the enterprise standard

     

    Usage

     

    Function of Vonoprazan Fumarate
    1) Prevention of duodenal ulcer and gastric ulcer recurrence

    A randomized, double-blind, multi-center clinical phase 3 trial comparing the effects of Voronazan fumarate (10mgqd and 20mgqd) and lansoprazole (15mgqd) on nonsteroidal anti-inflammatory drug-related peptic ulcer A total of 642 patients had been diagnosed with endoscopic peptic ulcers and needed to take non-steroidal anti-inflammatory drugs. The treatment period was 24 weeks. The primary endpoint was the proportion of duodenal ulcer and gastric ulcer recurrence at 24 weeks.

    2) Corrosive esophagitis (erosiveoesophagitis, EO)

    In a randomized, double-blind, multi-center, dose-range clinical phase 2 trial, in patients with EO, compared with lansoprazole, Voronazan fumarate showed non-inferiority and was rated in Los Angeles as C/D grade patients showed excellent effects, and oral administration of 20 mg once daily became the clinically recommended dose for the treatment of EO. A randomized, double-blind, multi-center clinical phase 3 trial comparing the efficacy of this product (20mgqd) and lansoprazole (30mgqd) on EO, a total of 409 patients participated in the study.

    3) Helicobacter pylori infection (Helicobacterpylori, Hp)

    A randomized, double-blind, multi-center clinical phase 3 trial comparing vonolazan fumarate (20mgbid) and lansoprazole (30mgbid), combined with amoxicillin and clarithromycin, to form a triple therapy, The effect of first-line medicine to eradicate Hp was included in a total of 650 Hp-positive patients who had had gastric ulcer or duodenal ulcer. The Hp eradication rates of this product and lansoprazole in the test group were 92.6% and 75.9%, respectively. For patients with clarithromycin resistance, the Hp eradication rates in the two test groups were 82.0% and 40.0%, respectively. Significantly superior to lansoprazole. In this trial, the first 50 patients who failed first-line treatment received second-line treatment with triple therapy of this product, amoxicillin and metronidazole, and the Hp clearance rate was 98%.

Send your message to this supplier
  • From:
  • To:
    Sinoway Industrial Co.Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service